Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Press Releases

9 Mar 2021

Tryp Therapeutics Appoints Luke Hayes as Chief Financial Officer

La Jolla, California–(Newsfile Corp....

By Microdose

Press Releases

9 Mar 2021

Pure Extracts and ShroomBloom Sign Psychedelic Mushroom Supply Letter of Intent

VANCOUVER, British Columbia, March 09, 2021 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp....

By Microdose

Press Releases

9 Mar 2021

Microdose Launches Special Report Spotlighting Intellectual Property & Patents in Psychedelic Drug Development

By Microdose

Press Releases

9 Mar 2021

New Wave Subsidiary, Way of Will Inc., to Roll Out All-Natural SPF Lotion in 2022

TORONTO, March 9, 2021 /CNW/ – NEW WAVE HOLDINGS CORP....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

9 Mar 2021

Awakn Acquires Proprietary Next Generation MDMA and Ketamine Data from Prof. David Nutt

London, United Kingdom–(Newsfile Corp....

By Microdose

Press Releases

9 Mar 2021

NeonMind Engages Pharma Executive Philippe Martin to Advance its Psilocybin Drug Candidates for Obesity

Vancouver, British Columbia–(Newsfile Corp....

By Microdose

Press Releases

8 Mar 2021

Pure Extracts Technologies Corp. Provides Update on Base Shelf Prospectus and Deemed Exercise of Special Warrants

Not for distribution to United States newswire services or for release, publication, distribution or dissemination, directly or indirectly, in whole or in part, in or into the United States....

By Microdose

Press Releases

8 Mar 2021

Lobe Sciences Completes Previously Announced Sale of Cannabis Assets to Ionic Brands

Vancouver, British Columbia–(Newsfile Corp....

By Microdose

Press Releases

8 Mar 2021

Mindset Pharma Appoints Leading Molecular Pharmacologist & Formulation Expert Dr. Joseph Gabriele to Scientific Advisory Board

Toronto, Ontario–(Newsfile Corp....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.